Page 1 of 108
WGU D027 Nursing Care of Older Adults
Objective Assessment – Latest Official Exam
with Complete 400 Questions and Verified
Detailed Answers
Official Exam Overview:
The WGU D027 OA assesses knowledge and practical application of care principles for older adults,
emphasizing physiological changes, pharmacology, cognitive health, and interventions to support
safety and quality of life. The exam evaluates learners’ understanding of age-related neurological,
cardiovascular, and musculoskeletal changes, as well as the use of medications to manage cognitive
disorders such as Alzheimer’s disease. Candidates must demonstrate comprehension of drug
mechanisms, therapeutic outcomes, and the rationale for pharmacologic interventions in older adults.
Exam Coverage Areas:
• Age-related changes in cognition and memory
• Neurodegenerative disorders, including Alzheimer’s disease
• Pharmacology for older adults: mechanisms, effects, and interactions
• Cholinesterase inhibitors and NMDA receptor antagonists (e.g., memantine)
• Nursing interventions to optimize cognitive function
• Patient safety, medication administration, and monitoring
• Therapeutic goals and adverse effect management
QUESTION 1:
What is the primary difference in mechanism of action (MOA) between cholinesterase inhibitors and
memantine (Namenda)?
A) Cholinesterase inhibitors regulate glutamate activity, memantine prevents acetylcholine
breakdown
B) Cholinesterase inhibitors prevent acetylcholine breakdown, memantine regulates glutamate
activity ✅
C) Both drugs prevent acetylcholine breakdown
D) Both drugs regulate dopamine activity
Rationale:
Cholinesterase inhibitors increase acetylcholine availability by preventing its breakdown,
improving communication between neurons. Memantine (Namenda) modulates glutamate activity
to protect neurons from excitotoxicity, targeting a different pathway in cognitive function.
,QUESTION 2:
Cholinesterase inhibitors are primarily used to treat which condition in older adults?
A) Hypertension
B) Alzheimer’s disease ✅
C) Diabetes mellitus
D) Osteoporosis
Rationale:
By enhancing acetylcholine, cholinesterase inhibitors improve memory and cognition in patients
with Alzheimer’s disease.
QUESTION 3:
Memantine (Namenda) works by affecting which neurotransmitter system?
A) Dopamine
B) Serotonin
C) Glutamate ✅
D) Norepinephrine
Rationale:
Memantine is an NMDA receptor antagonist, regulating glutamate, the primary excitatory
neurotransmitter in the CNS, to prevent neuronal damage.
QUESTION 4:
Why might a clinician prescribe memantine instead of a cholinesterase inhibitor?
A) For early-stage Alzheimer’s
B) To reduce excitotoxic neuronal damage in moderate-to-severe Alzheimer’s ✅
C) To lower blood pressure
D) To prevent falls
Rationale:
Memantine is commonly prescribed in moderate-to-severe Alzheimer’s, targeting excess
glutamate activity rather than acetylcholine.
QUESTION 5:
Which of the following represents a complementary effect when combining cholinesterase inhibitors
with memantine?
A) Both drugs inhibit acetylcholine breakdown
B) One improves acetylcholine signaling, the other protects neurons from glutamate toxicity ✅
C) Both drugs increase dopamine levels
D) Both drugs reduce serotonin activity
Rationale:
Combining cholinesterase inhibitors and memantine provides a dual mechanism: improved
,neurotransmission via acetylcholine and protection against glutamate-mediated excitotoxicity,
supporting cognition in Alzheimer’s patients.
What is the difference in MOA between cholinesterase inhibitors and memantine (namenda)? -
ANSWER-- Cholinesterase inhibitors prevent the breakdown of acetylcholine, whereas
memantine (namenda) regulates the activity of glutamate
What is ataxia? - ANSWER-- Also known as cerebellum attacks
- Degenerative disease of the nervous system
- Many symptoms mimic those of being drunk (i.e. slurred speech, stumbling, falling, and
incoordination)
What causes the symptoms of ataxia? - ANSWER-- The damage caused to the cerebellum, the
part of the brain that is responsible for coordinating movements
- Can also be caused by damage to part of the spinal cord and nerves
What is the treatment for ataxia? - ANSWER-- No treatment
- In some cases, treating the underlying causes (i.e. stopping medications that cause ataxia)
- In other cases, it is a result from chicken pox or other viral infections (likely to resolve on its
own)
1
, Page 2 of 108
- Genetic causes/predisposed disposition is usually chronic
What causes ataxia in the pediatric population? - ANSWER-- Genetic predisposition
- Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)
- Prader-Willie Syndrome
What is Fragile X syndrome (FXS)? - ANSWER-- A genetic condition inherited from parents which
results in various developmental problems
- Rare, but may be dangerous or life-threatening
- Present at birth and is a lifelong condition
- Rarely requires lab testing or imaging
- Often linked to autism (1/3 do have autism)
- X-linked disorder
Since Fragile X Syndrome (FXS) is an X-linked disorder, does a specific gender have a greater
risk? - ANSWER-- Often, females are carriers and males are affected
- However, both males and females can be carriers, and both can be affected by the condition
- Usually milder in females
2
WGU D027 Nursing Care of Older Adults
Objective Assessment – Latest Official Exam
with Complete 400 Questions and Verified
Detailed Answers
Official Exam Overview:
The WGU D027 OA assesses knowledge and practical application of care principles for older adults,
emphasizing physiological changes, pharmacology, cognitive health, and interventions to support
safety and quality of life. The exam evaluates learners’ understanding of age-related neurological,
cardiovascular, and musculoskeletal changes, as well as the use of medications to manage cognitive
disorders such as Alzheimer’s disease. Candidates must demonstrate comprehension of drug
mechanisms, therapeutic outcomes, and the rationale for pharmacologic interventions in older adults.
Exam Coverage Areas:
• Age-related changes in cognition and memory
• Neurodegenerative disorders, including Alzheimer’s disease
• Pharmacology for older adults: mechanisms, effects, and interactions
• Cholinesterase inhibitors and NMDA receptor antagonists (e.g., memantine)
• Nursing interventions to optimize cognitive function
• Patient safety, medication administration, and monitoring
• Therapeutic goals and adverse effect management
QUESTION 1:
What is the primary difference in mechanism of action (MOA) between cholinesterase inhibitors and
memantine (Namenda)?
A) Cholinesterase inhibitors regulate glutamate activity, memantine prevents acetylcholine
breakdown
B) Cholinesterase inhibitors prevent acetylcholine breakdown, memantine regulates glutamate
activity ✅
C) Both drugs prevent acetylcholine breakdown
D) Both drugs regulate dopamine activity
Rationale:
Cholinesterase inhibitors increase acetylcholine availability by preventing its breakdown,
improving communication between neurons. Memantine (Namenda) modulates glutamate activity
to protect neurons from excitotoxicity, targeting a different pathway in cognitive function.
,QUESTION 2:
Cholinesterase inhibitors are primarily used to treat which condition in older adults?
A) Hypertension
B) Alzheimer’s disease ✅
C) Diabetes mellitus
D) Osteoporosis
Rationale:
By enhancing acetylcholine, cholinesterase inhibitors improve memory and cognition in patients
with Alzheimer’s disease.
QUESTION 3:
Memantine (Namenda) works by affecting which neurotransmitter system?
A) Dopamine
B) Serotonin
C) Glutamate ✅
D) Norepinephrine
Rationale:
Memantine is an NMDA receptor antagonist, regulating glutamate, the primary excitatory
neurotransmitter in the CNS, to prevent neuronal damage.
QUESTION 4:
Why might a clinician prescribe memantine instead of a cholinesterase inhibitor?
A) For early-stage Alzheimer’s
B) To reduce excitotoxic neuronal damage in moderate-to-severe Alzheimer’s ✅
C) To lower blood pressure
D) To prevent falls
Rationale:
Memantine is commonly prescribed in moderate-to-severe Alzheimer’s, targeting excess
glutamate activity rather than acetylcholine.
QUESTION 5:
Which of the following represents a complementary effect when combining cholinesterase inhibitors
with memantine?
A) Both drugs inhibit acetylcholine breakdown
B) One improves acetylcholine signaling, the other protects neurons from glutamate toxicity ✅
C) Both drugs increase dopamine levels
D) Both drugs reduce serotonin activity
Rationale:
Combining cholinesterase inhibitors and memantine provides a dual mechanism: improved
,neurotransmission via acetylcholine and protection against glutamate-mediated excitotoxicity,
supporting cognition in Alzheimer’s patients.
What is the difference in MOA between cholinesterase inhibitors and memantine (namenda)? -
ANSWER-- Cholinesterase inhibitors prevent the breakdown of acetylcholine, whereas
memantine (namenda) regulates the activity of glutamate
What is ataxia? - ANSWER-- Also known as cerebellum attacks
- Degenerative disease of the nervous system
- Many symptoms mimic those of being drunk (i.e. slurred speech, stumbling, falling, and
incoordination)
What causes the symptoms of ataxia? - ANSWER-- The damage caused to the cerebellum, the
part of the brain that is responsible for coordinating movements
- Can also be caused by damage to part of the spinal cord and nerves
What is the treatment for ataxia? - ANSWER-- No treatment
- In some cases, treating the underlying causes (i.e. stopping medications that cause ataxia)
- In other cases, it is a result from chicken pox or other viral infections (likely to resolve on its
own)
1
, Page 2 of 108
- Genetic causes/predisposed disposition is usually chronic
What causes ataxia in the pediatric population? - ANSWER-- Genetic predisposition
- Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)
- Prader-Willie Syndrome
What is Fragile X syndrome (FXS)? - ANSWER-- A genetic condition inherited from parents which
results in various developmental problems
- Rare, but may be dangerous or life-threatening
- Present at birth and is a lifelong condition
- Rarely requires lab testing or imaging
- Often linked to autism (1/3 do have autism)
- X-linked disorder
Since Fragile X Syndrome (FXS) is an X-linked disorder, does a specific gender have a greater
risk? - ANSWER-- Often, females are carriers and males are affected
- However, both males and females can be carriers, and both can be affected by the condition
- Usually milder in females
2
